Rheumatology Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapeutic Molecule (Pharmaceuticals, Biopharmaceuticals); Route of Administration (Oral, Parenteral) and Geography
Report Code: TIPRE00017834 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease, which generally leads to disability, progressive joint deformity, and occasionally premature death. RA may affect many tissues and organs, but it principally attacks the joints, producing an inflammatory synovitis that often progresses to destruction of the articular cartilage and ankylosis of the joints. The treatment options available for rheumatoid arthritis are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (biologics).
MARKET DYNAMICS
The Rheumatology Drugs market is driving due to the rise in prevalence of arthritis, increasing acceptance of biopharmaceuticals, and presence of well-defined regulatory guidelines in developed economies. However, the accessibility of the treatment, patent expiration of blockbuster drugs and alternative treatment options for rheumatoid arthritis are projected to hamper the market growth.
MARKET SCOPE
The "Rheumatology Drugs Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Rheumatology Drugs market with detailed market segmentation by therapeutic molecule and route of administration. The Rheumatology Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Rheumatology Drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Rheumatology Drugs market is segmented on the basis of therapeutic molecule and route of administration. On the basis of therapeutic molecule, the market is categorized as pharmaceuticals, biopharmaceuticals. Pharmaceuticals segment is further segmented into NSAIDs, analgesics, DMARDs and corticosteroids. Biopharmaceuticals segment is further segmented into biologics and biosimilars. On the basis of route of administration, the market is categorized oral and parenteral..
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Rheumatology Drugs market based on various segments. It also provides market size and forecast estimates from year 2018 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Rheumatology Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Rheumatology Drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Rheumatology Drugs market in these regions.
The report covers key developments in the Rheumatology Drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Rheumatology Drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for Rheumatology Drugs in the global market. Below mentioned is the list of few companies engaged in the Rheumatology Drugs market.
The report also includes the profiles of key players in Rheumatology Drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Rheumatoid arthritis (RA) is a chronic inflammatory disease, which generally leads to disability, progressive joint deformity, and occasionally premature death. RA may affect many tissues and organs, but it principally attacks the joints, producing an inflammatory synovitis that often progresses to destruction of the articular cartilage and ankylosis of the joints. The treatment options available for rheumatoid arthritis are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (biologics).
MARKET DYNAMICS
The Rheumatology Drugs market is driving due to the rise in prevalence of arthritis, increasing acceptance of biopharmaceuticals, and presence of well-defined regulatory guidelines in developed economies. However, the accessibility of the treatment, patent expiration of blockbuster drugs and alternative treatment options for rheumatoid arthritis are projected to hamper the market growth.
MARKET SCOPE
The "Rheumatology Drugs Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Rheumatology Drugs market with detailed market segmentation by therapeutic molecule and route of administration. The Rheumatology Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Rheumatology Drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Rheumatology Drugs market is segmented on the basis of therapeutic molecule and route of administration. On the basis of therapeutic molecule, the market is categorized as pharmaceuticals, biopharmaceuticals. Pharmaceuticals segment is further segmented into NSAIDs, analgesics, DMARDs and corticosteroids. Biopharmaceuticals segment is further segmented into biologics and biosimilars. On the basis of route of administration, the market is categorized oral and parenteral..
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Rheumatology Drugs market based on various segments. It also provides market size and forecast estimates from year 2018 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Rheumatology Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Rheumatology Drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Rheumatology Drugs market in these regions.
The report covers key developments in the Rheumatology Drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Rheumatology Drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for Rheumatology Drugs in the global market. Below mentioned is the list of few companies engaged in the Rheumatology Drugs market.
The report also includes the profiles of key players in Rheumatology Drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- AbbVie
- Regeneron Pharmaceuticals, Inc.
- Novartis International AG
- Pfizer Inc.
- Bristol-Myers Squibb.
- Hoffmann-La Roche AG
- Johnson and Johnson
- Boehringer Ingelheim GmbH
- UCB S.A.
- Amgen Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Rheumatology Drugs Market - By Therapeutic Molecule
1.3.2 Rheumatology Drugs Market - By Route of Administration
1.3.3 Rheumatology Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RHEUMATOLOGY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RHEUMATOLOGY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RHEUMATOLOGY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. RHEUMATOLOGY DRUGS - GLOBAL MARKET OVERVIEW
6.2. RHEUMATOLOGY DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. RHEUMATOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC MOLECULE
7.1. OVERVIEW
7.2. THERAPEUTIC MOLECULE MARKET FORECASTS AND ANALYSIS
7.3. PHARMACEUTICALS
7.3.1. Overview
7.3.2. Pharmaceuticals Market Forecast and Analysis
7.3.3. NSAIDs Market
7.3.3.1. Overview
7.3.3.2. NSAIDs Market Forecast and Analysis
7.3.4. Analgesics Market
7.3.4.1. Overview
7.3.4.2. Analgesics Market Forecast and Analysis
7.3.5. DMARDs Market
7.3.5.1. Overview
7.3.5.2. DMARDs Market Forecast and Analysis
7.3.6. Corticosteroids Market
7.3.6.1. Overview
7.3.6.2. Corticosteroids Market Forecast and Analysis
7.4. BIOPHARMACEUTICALS
7.4.1. Overview
7.4.2. Biopharmaceuticals Market Forecast and Analysis
7.4.3. Biologics Market
7.4.3.1. Overview
7.4.3.2. Biologics Market Forecast and Analysis
7.4.4. Biosimilars Market
7.4.4.1. Overview
7.4.4.2. Biosimilars Market Forecast and Analysis
8. RHEUMATOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. PARENTERAL
8.4.1. Overview
8.4.2. Parenteral Market Forecast and Analysis
9. RHEUMATOLOGY DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Rheumatology Drugs Market Overview
9.1.2 North America Rheumatology Drugs Market Forecasts and Analysis
9.1.3 North America Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.1.4 North America Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.1.5 North America Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Rheumatology Drugs Market
9.1.5.1.1 United States Rheumatology Drugs Market by Therapeutic Molecule
9.1.5.1.2 United States Rheumatology Drugs Market by Route of Administration
9.1.5.2 Canada Rheumatology Drugs Market
9.1.5.2.1 Canada Rheumatology Drugs Market by Therapeutic Molecule
9.1.5.2.2 Canada Rheumatology Drugs Market by Route of Administration
9.2. EUROPE
9.2.1 Europe Rheumatology Drugs Market Overview
9.2.2 Europe Rheumatology Drugs Market Forecasts and Analysis
9.2.3 Europe Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.2.4 Europe Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.2.5 Europe Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Rheumatology Drugs Market
9.2.5.1.1 Germany Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.1.2 Germany Rheumatology Drugs Market by Route of Administration
9.2.5.2 France Rheumatology Drugs Market
9.2.5.2.1 France Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.2.2 France Rheumatology Drugs Market by Route of Administration
9.2.5.3 Italy Rheumatology Drugs Market
9.2.5.3.1 Italy Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.3.2 Italy Rheumatology Drugs Market by Route of Administration
9.2.5.4 Spain Rheumatology Drugs Market
9.2.5.4.1 Spain Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.4.2 Spain Rheumatology Drugs Market by Route of Administration
9.2.5.5 United Kingdom Rheumatology Drugs Market
9.2.5.5.1 United Kingdom Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.5.2 United Kingdom Rheumatology Drugs Market by Route of Administration
9.2.5.6 Rest of Europe Rheumatology Drugs Market
9.2.5.6.1 Rest of Europe Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.6.2 Rest of Europe Rheumatology Drugs Market by Route of Administration
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Rheumatology Drugs Market Overview
9.3.2 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.3.4 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.3.5 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Rheumatology Drugs Market
9.3.5.1.1 Australia Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.1.2 Australia Rheumatology Drugs Market by Route of Administration
9.3.5.2 China Rheumatology Drugs Market
9.3.5.2.1 China Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.2.2 China Rheumatology Drugs Market by Route of Administration
9.3.5.3 India Rheumatology Drugs Market
9.3.5.3.1 India Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.3.2 India Rheumatology Drugs Market by Route of Administration
9.3.5.4 Japan Rheumatology Drugs Market
9.3.5.4.1 Japan Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.4.2 Japan Rheumatology Drugs Market by Route of Administration
9.3.5.5 South Korea Rheumatology Drugs Market
9.3.5.5.1 South Korea Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.5.2 South Korea Rheumatology Drugs Market by Route of Administration
9.3.5.6 Rest of Asia-Pacific Rheumatology Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.6.2 Rest of Asia-Pacific Rheumatology Drugs Market by Route of Administration
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Rheumatology Drugs Market Overview
9.4.2 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.4.4 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.4.5 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Rheumatology Drugs Market
9.4.5.1.1 South Africa Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.1.2 South Africa Rheumatology Drugs Market by Route of Administration
9.4.5.2 Saudi Arabia Rheumatology Drugs Market
9.4.5.2.1 Saudi Arabia Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.2.2 Saudi Arabia Rheumatology Drugs Market by Route of Administration
9.4.5.3 U.A.E Rheumatology Drugs Market
9.4.5.3.1 U.A.E Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.3.2 U.A.E Rheumatology Drugs Market by Route of Administration
9.4.5.4 Rest of Middle East and Africa Rheumatology Drugs Market
9.4.5.4.1 Rest of Middle East and Africa Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.4.2 Rest of Middle East and Africa Rheumatology Drugs Market by Route of Administration
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Rheumatology Drugs Market Overview
9.5.2 South and Central America Rheumatology Drugs Market Forecasts and Analysis
9.5.3 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.5.4 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.5.5 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Rheumatology Drugs Market
9.5.5.1.1 Brazil Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.1.2 Brazil Rheumatology Drugs Market by Route of Administration
9.5.5.2 Argentina Rheumatology Drugs Market
9.5.5.2.1 Argentina Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.2.2 Argentina Rheumatology Drugs Market by Route of Administration
9.5.5.3 Rest of South and Central America Rheumatology Drugs Market
9.5.5.3.1 Rest of South and Central America Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.3.2 Rest of South and Central America Rheumatology Drugs Market by Route of Administration
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. RHEUMATOLOGY DRUGS MARKET, KEY COMPANY PROFILES
11.1. ABBVIE
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. REGENERON PHARMACEUTICALS, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS INTERNATIONAL AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BRISTOL-MYERS SQUIBB.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. HOFFMANN-LA ROCHE AG
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. JOHNSON AND JOHNSON
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BOEHRINGER INGELHEIM GMBH
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. UCB S.A.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. AMGEN INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Rheumatology Drugs Market - By Therapeutic Molecule
1.3.2 Rheumatology Drugs Market - By Route of Administration
1.3.3 Rheumatology Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RHEUMATOLOGY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RHEUMATOLOGY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RHEUMATOLOGY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. RHEUMATOLOGY DRUGS - GLOBAL MARKET OVERVIEW
6.2. RHEUMATOLOGY DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. RHEUMATOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC MOLECULE
7.1. OVERVIEW
7.2. THERAPEUTIC MOLECULE MARKET FORECASTS AND ANALYSIS
7.3. PHARMACEUTICALS
7.3.1. Overview
7.3.2. Pharmaceuticals Market Forecast and Analysis
7.3.3. NSAIDs Market
7.3.3.1. Overview
7.3.3.2. NSAIDs Market Forecast and Analysis
7.3.4. Analgesics Market
7.3.4.1. Overview
7.3.4.2. Analgesics Market Forecast and Analysis
7.3.5. DMARDs Market
7.3.5.1. Overview
7.3.5.2. DMARDs Market Forecast and Analysis
7.3.6. Corticosteroids Market
7.3.6.1. Overview
7.3.6.2. Corticosteroids Market Forecast and Analysis
7.4. BIOPHARMACEUTICALS
7.4.1. Overview
7.4.2. Biopharmaceuticals Market Forecast and Analysis
7.4.3. Biologics Market
7.4.3.1. Overview
7.4.3.2. Biologics Market Forecast and Analysis
7.4.4. Biosimilars Market
7.4.4.1. Overview
7.4.4.2. Biosimilars Market Forecast and Analysis
8. RHEUMATOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. PARENTERAL
8.4.1. Overview
8.4.2. Parenteral Market Forecast and Analysis
9. RHEUMATOLOGY DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Rheumatology Drugs Market Overview
9.1.2 North America Rheumatology Drugs Market Forecasts and Analysis
9.1.3 North America Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.1.4 North America Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.1.5 North America Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Rheumatology Drugs Market
9.1.5.1.1 United States Rheumatology Drugs Market by Therapeutic Molecule
9.1.5.1.2 United States Rheumatology Drugs Market by Route of Administration
9.1.5.2 Canada Rheumatology Drugs Market
9.1.5.2.1 Canada Rheumatology Drugs Market by Therapeutic Molecule
9.1.5.2.2 Canada Rheumatology Drugs Market by Route of Administration
9.2. EUROPE
9.2.1 Europe Rheumatology Drugs Market Overview
9.2.2 Europe Rheumatology Drugs Market Forecasts and Analysis
9.2.3 Europe Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.2.4 Europe Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.2.5 Europe Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Rheumatology Drugs Market
9.2.5.1.1 Germany Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.1.2 Germany Rheumatology Drugs Market by Route of Administration
9.2.5.2 France Rheumatology Drugs Market
9.2.5.2.1 France Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.2.2 France Rheumatology Drugs Market by Route of Administration
9.2.5.3 Italy Rheumatology Drugs Market
9.2.5.3.1 Italy Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.3.2 Italy Rheumatology Drugs Market by Route of Administration
9.2.5.4 Spain Rheumatology Drugs Market
9.2.5.4.1 Spain Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.4.2 Spain Rheumatology Drugs Market by Route of Administration
9.2.5.5 United Kingdom Rheumatology Drugs Market
9.2.5.5.1 United Kingdom Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.5.2 United Kingdom Rheumatology Drugs Market by Route of Administration
9.2.5.6 Rest of Europe Rheumatology Drugs Market
9.2.5.6.1 Rest of Europe Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.6.2 Rest of Europe Rheumatology Drugs Market by Route of Administration
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Rheumatology Drugs Market Overview
9.3.2 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.3.4 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.3.5 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Rheumatology Drugs Market
9.3.5.1.1 Australia Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.1.2 Australia Rheumatology Drugs Market by Route of Administration
9.3.5.2 China Rheumatology Drugs Market
9.3.5.2.1 China Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.2.2 China Rheumatology Drugs Market by Route of Administration
9.3.5.3 India Rheumatology Drugs Market
9.3.5.3.1 India Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.3.2 India Rheumatology Drugs Market by Route of Administration
9.3.5.4 Japan Rheumatology Drugs Market
9.3.5.4.1 Japan Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.4.2 Japan Rheumatology Drugs Market by Route of Administration
9.3.5.5 South Korea Rheumatology Drugs Market
9.3.5.5.1 South Korea Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.5.2 South Korea Rheumatology Drugs Market by Route of Administration
9.3.5.6 Rest of Asia-Pacific Rheumatology Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.6.2 Rest of Asia-Pacific Rheumatology Drugs Market by Route of Administration
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Rheumatology Drugs Market Overview
9.4.2 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.4.4 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.4.5 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Rheumatology Drugs Market
9.4.5.1.1 South Africa Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.1.2 South Africa Rheumatology Drugs Market by Route of Administration
9.4.5.2 Saudi Arabia Rheumatology Drugs Market
9.4.5.2.1 Saudi Arabia Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.2.2 Saudi Arabia Rheumatology Drugs Market by Route of Administration
9.4.5.3 U.A.E Rheumatology Drugs Market
9.4.5.3.1 U.A.E Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.3.2 U.A.E Rheumatology Drugs Market by Route of Administration
9.4.5.4 Rest of Middle East and Africa Rheumatology Drugs Market
9.4.5.4.1 Rest of Middle East and Africa Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.4.2 Rest of Middle East and Africa Rheumatology Drugs Market by Route of Administration
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Rheumatology Drugs Market Overview
9.5.2 South and Central America Rheumatology Drugs Market Forecasts and Analysis
9.5.3 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.5.4 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.5.5 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Rheumatology Drugs Market
9.5.5.1.1 Brazil Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.1.2 Brazil Rheumatology Drugs Market by Route of Administration
9.5.5.2 Argentina Rheumatology Drugs Market
9.5.5.2.1 Argentina Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.2.2 Argentina Rheumatology Drugs Market by Route of Administration
9.5.5.3 Rest of South and Central America Rheumatology Drugs Market
9.5.5.3.1 Rest of South and Central America Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.3.2 Rest of South and Central America Rheumatology Drugs Market by Route of Administration
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. RHEUMATOLOGY DRUGS MARKET, KEY COMPANY PROFILES
11.1. ABBVIE
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. REGENERON PHARMACEUTICALS, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS INTERNATIONAL AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BRISTOL-MYERS SQUIBB.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. HOFFMANN-LA ROCHE AG
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. JOHNSON AND JOHNSON
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BOEHRINGER INGELHEIM GMBH
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. UCB S.A.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. AMGEN INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. AbbVie
2. Regeneron Pharmaceuticals, Inc.
3. Novartis International AG
4. Pfizer Inc.
5. Bristol-Myers Squibb.
6. Hoffmann-La Roche AG
7. Johnson and Johnson
8. Boehringer Ingelheim GmbH
9. UCB S.A.
10. Amgen Inc.
2. Regeneron Pharmaceuticals, Inc.
3. Novartis International AG
4. Pfizer Inc.
5. Bristol-Myers Squibb.
6. Hoffmann-La Roche AG
7. Johnson and Johnson
8. Boehringer Ingelheim GmbH
9. UCB S.A.
10. Amgen Inc.